138 related articles for article (PubMed ID: 25625043)
1. Treatment patterns for ductal carcinoma in situ from 2000-2010 across six integrated health plans.
Feigelson HS; Carroll NM; Weinmann S; Haque R; Yu CL; Butler MG; Waitzfelder B; Wrenn MG; Capra A; McGlynn EA; Habel LA
Springerplus; 2015; 4():24. PubMed ID: 25625043
[TBL] [Abstract][Full Text] [Related]
2. The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists.
CMAJ; 1998 Feb; 158 Suppl 3():S27-34. PubMed ID: 9484276
[TBL] [Abstract][Full Text] [Related]
3. Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ.
Shiyanbola OO; Sprague BL; Hampton JM; Dittus K; James TA; Herschorn S; Gangnon RE; Weaver DL; Trentham-Dietz A
Cancer; 2016 Sep; 122(18):2810-8. PubMed ID: 27244699
[TBL] [Abstract][Full Text] [Related]
4. Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ.
Hassett MJ; Jiang W; Hughes ME; Edge S; Javid SH; Niland JC; Theriault R; Wong YN; Schrag D; Punglia RS
J Natl Compr Canc Netw; 2018 Apr; 16(4):387-394. PubMed ID: 29632058
[No Abstract] [Full Text] [Related]
5. Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women.
Buscariollo DL; Cronin AM; Borstelmann NA; Punglia RS
Breast Cancer Res Treat; 2019 Feb; 173(3):709-717. PubMed ID: 30406869
[TBL] [Abstract][Full Text] [Related]
6. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
[TBL] [Abstract][Full Text] [Related]
7. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast.
Hillner BE; Desch CE; Carlson RW; Smith TJ; Esserman L; Bear HD
J Clin Oncol; 1996 Jan; 14(1):70-7. PubMed ID: 8558224
[TBL] [Abstract][Full Text] [Related]
8. Variations in treatment for ductal carcinoma in situ in elderly women.
Gold HT; Dick AW
Med Care; 2004 Mar; 42(3):267-75. PubMed ID: 15076826
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Surgical Options for Patients with Ductal Carcinoma In Situ: An Instrumental Variable Approach.
Duan L; Kawatkar AA
Perm J; 2018; 22():17-132. PubMed ID: 30028673
[TBL] [Abstract][Full Text] [Related]
10. Effect of Referral Patterns and Treatment Type on Oncologic Outcomes for Women with Ductal Carcinoma In Situ.
Wai ES; Lesperance M; Lu L; Alexander CS; Truong PT
Cureus; 2017 Mar; 9(3):e1128. PubMed ID: 28465875
[TBL] [Abstract][Full Text] [Related]
11. Incidence of and treatment for ductal carcinoma in situ of the breast.
Ernster VL; Barclay J; Kerlikowske K; Grady D; Henderson C
JAMA; 1996 Mar; 275(12):913-8. PubMed ID: 8598618
[TBL] [Abstract][Full Text] [Related]
12. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
[TBL] [Abstract][Full Text] [Related]
13. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival.
Joslyn SA
Breast J; 2006; 12(1):20-7. PubMed ID: 16409583
[TBL] [Abstract][Full Text] [Related]
14. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ.
Tuttle TM; Jarosek S; Habermann EB; Arrington A; Abraham A; Morris TJ; Virnig BA
J Clin Oncol; 2009 Mar; 27(9):1362-7. PubMed ID: 19224844
[TBL] [Abstract][Full Text] [Related]
15. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
Rakovitch E; Nofech-Mozes S; Narod SA; Hanna W; Thiruchelvam D; Saskin R; Taylor C; Tuck A; Sengupta S; Elavathil L; Jani PA; Done SJ; Miller N; Youngson B; Kong I; Paszat L
Breast Cancer Res Treat; 2013 Apr; 138(2):581-90. PubMed ID: 23456231
[TBL] [Abstract][Full Text] [Related]
16. Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort.
Sprague BL; Vacek PM; Herschorn SD; James TA; Geller BM; Trentham-Dietz A; Stein JL; Weaver DL
Breast Cancer Res Treat; 2019 Feb; 174(1):227-235. PubMed ID: 30448897
[TBL] [Abstract][Full Text] [Related]
17. Disparities in the Initial Local Treatment of Older Women with Early-Stage Breast Cancer: A Population-Based Study.
LeMasters TJ; Madhavan SS; Sambamoorthi U; Vyas AM
J Womens Health (Larchmt); 2017 Jul; 26(7):735-744. PubMed ID: 28170302
[TBL] [Abstract][Full Text] [Related]
18. Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm.
Hamilton SN; Nichol A; Wai E; Gondara L; Velásquez García HA; Speers C; Diocee R; Truong P
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):381-388. PubMed ID: 30253237
[TBL] [Abstract][Full Text] [Related]
19. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy.
Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Gu S; Fong C; Tuck A; Youngson B; Miller N; Done SJ; Chang MC; Sengupta S; Elavathil L; Jani PA; Bonin M; Lalani N; Paszat L
Breast; 2018 Feb; 37():181-186. PubMed ID: 28781102
[TBL] [Abstract][Full Text] [Related]
20. Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013.
Sagara Y; Freedman RA; Wong SM; Aydogan F; Nguyen A; Barry WT; Golshan M
Breast Cancer Res Treat; 2017 Nov; 166(2):583-592. PubMed ID: 28776282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
